作者: Eun Hye Kim , Se Woo Park , Eunwoo Nam , Jae Gon Lee , Chan Hyuk Park
DOI: 10.1007/S00464-018-6409-4
关键词:
摘要: The comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection (ESD) has not been fully evaluated. Recently, vonoprazan, a novel potassium-competitive acid blocker, also used in ulcer treatment ESD. We searched for all relevant randomized controlled trials examining the ESD, published through October 2017. Healing iatrogenic ulcers was investigated at 4–8 weeks A network meta-analysis performed to calculate estimates. Twenty-one studies with 2005 patients were included. Concerning healing 4 weeks no inconsistency identified (Cochran’s Q-test, df = 10, P = 0.13; I2 = 34%). combination therapy proton-pump inhibitor (PPI) and muco-protective agent superior PPI alone [risk ratio (RR) (95% confidence interval, CI) 1.69 (1.20–2.39)]. agents tended be vonoprazan [RR 1.98 (0.99–3.94)]. There difference effect between vs. 1.17 (0.64–2.12)]. rate 8 weeks however, 1.27 (1.03–1.56)]. Additionally, 1.20 (0.96–1.51)]. In PPI.